GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
Stock Information for GT Biopharma Inc.
Loading
Please wait while we load your information from QuoteMedia.